Clinical Trial Detail

NCT ID NCT03455270
Title G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements yes
Sponsors G1 Therapeutics, Inc.
Indications

Her2-receptor negative breast cancer

Therapies

G1T48

Age Groups: senior adult

Additional content available in CKB BOOST